Salim Syed
Stock Analyst at Mizuho
(1.82)
# 3,290
Out of 5,008 analysts
75
Total ratings
43.33%
Success rate
-0.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.06 | +579.61% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $60.17 | +39.60% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $152.21 | +11.03% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $295.54 | -5.26% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $116.78 | +0.19% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $7.19 | +205.98% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $41.87 | +289.30% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $15.63 | +15.16% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $20.13 | +68.90% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $70.62 | +40.19% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $54.22 | -2.25% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.71 | +1,128.07% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $23.86 | +50.88% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.06
Upside: +579.61%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $60.17
Upside: +39.60%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $152.21
Upside: +11.03%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $295.54
Upside: -5.26%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $116.78
Upside: +0.19%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $7.19
Upside: +205.98%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $41.87
Upside: +289.30%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $15.63
Upside: +15.16%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $20.13
Upside: +68.90%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $70.62
Upside: +40.19%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $54.22
Upside: -2.25%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.71
Upside: +1,128.07%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $23.86
Upside: +50.88%